BERKELEY, Calif., Aug. 16 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the U.S. Patent Office has issued the company a broad composition of matter patent covering the company's proprietary second-generation TLR9 agonists.
The claims cover a broad class of novel TLR9 agonists containing short DNA sequences separated by spacer molecules. These linear chimeric immunomodulatory compounds (CICs), are being developed at Dynavax for application across a wide range of therapeutic categories. The claims cover CICs with or without antigen, and alone or in a pharmaceutical preparation. The current term for this patent expires in June 2022. The patent, U.S. patent No. 7,255,868 B2, was issued August 14, 2007 with inventors Karen Fearon, Dino Dina, M.D., and Stephen Tuck.
According to Dino Dina, M.D., President and Chief Executive Officer, "We developed the second-generation TLR9 agonists specifically to gain broad patent coverage for a full range of products in our pipeline. The issuance of this landmark patent provides broad patent coverage for novel and non-obvious molecules that are completely different from our first generation TLR9 agonists. We have pending applications in this family that we believe have the potential to expand the scope of coverage."
Dynavax Technologies Corporation discovers, develops, and intends to
commercialize innovative TLR9 agonist-based products to treat and prevent
infectious diseases, allergies, cancer, and chronic inflammatory diseases
using versatile, proprietary approaches that alter immune system responses
in highly specific ways. Our TLR9 agonists are based on immunostimulatory
sequences, or ISS, which ar
|SOURCE Dynavax Technologies Corporation|
Copyright©2007 PR Newswire.